Evaluation of axitinib to downstage cT2a renal tumours and allow partial nephrectomy: a phase II study

ConclusionNeoadjuvant axitinib in cT2 ccRCC is feasible and, even with a modest decrease in size, allowed a tumour shrinkage<7  cm in 12 cases; however, PN procedures remained complex, requiring surgical expertise with possible morbidity.

Source: BJU International - November 20, 2018 Category: Urology & Nephrology Authors: Cedric Lebacle, Karim Bensalah, Jean ‐Christophe Bernhard, Laurence Albiges, Brigitte Laguerre, Marine Gross‐Goupil, Herve Baumert, Herve Lang, Thibault Tricard, Brigitte Duclos, Armelle Arnoux, Celine Piedvache, Jean‐Jacques Patard, Be Tags: Original Article Source Type: research